OBJECTIVE: To investigate the neural substrate of premenstrual dysphoric disorder (PMDD), the authors used [15O]H2O positron emission tomography (PET) regional cerebral blood flow (rCBF) and blood-oxygen-level-dependent (BOLD) functional MRI (fMRI) signal measurements during working memory in conjunction with a 6-month hormone manipulation protocol. METHOD: PET and fMRI scans were obtained from women with prospectively confirmed PMDD and asymptomatic comparison subjects while they completed the n-back task during three hormone conditions: ovarian suppression induced by the gonadotropin-releasing hormone agonist leuprolide acetate, leuprolide plus estradiol, and leuprolide plus progesterone. Fifteen patients and 15 matched comparison subjects underwent PET imaging. Fourteen patients and 14 comparison subjects underwent fMRI. For each hormone condition, rCBF was measured with [15O]H2O PET, and BOLD signal was measured with fMRI, both during an n-back working memory paradigm. Global Assessment of Functioning Scale (GAF) scores and clinical characteristics were obtained for each patient before hormone manipulation, and symptoms were measured before and during the protocol. RESULTS: In both the PET and fMRI studies, a main effect of diagnosis was observed, with PMDD patients showing greater prefrontal activation than comparison subjects. In the patient group, the degree to which dorsolateral prefrontal cortex activation was abnormally increased correlated with several dimensions of disease: disability as indicated by GAF scores, age at symptom onset, duration of PMDD, and differences in pre- and postmenses PMDD symptoms. CONCLUSIONS: Abnormal working memory activation in PMDD, specifically in the dorsolateral prefrontal cortex, is related to PMDD severity, symptoms, age at onset, and disease burden. These results support the clinical relevance of the findings and the proposal that dorsolateral prefrontal cortex dysfunction represents a substrate of risk for PMDD. The concordance of the fMRI and PET data attests to the neurobiological validity of the results.
OBJECTIVE: To investigate the neural substrate of premenstrual dysphoric disorder (PMDD), the authors used [15O]H2O positron emission tomography (PET) regional cerebral blood flow (rCBF) and blood-oxygen-level-dependent (BOLD) functional MRI (fMRI) signal measurements during working memory in conjunction with a 6-month hormone manipulation protocol. METHOD: PET and fMRI scans were obtained from women with prospectively confirmed PMDD and asymptomatic comparison subjects while they completed the n-back task during three hormone conditions: ovarian suppression induced by the gonadotropin-releasing hormone agonist leuprolide acetate, leuprolide plus estradiol, and leuprolide plus progesterone. Fifteen patients and 15 matched comparison subjects underwent PET imaging. Fourteen patients and 14 comparison subjects underwent fMRI. For each hormone condition, rCBF was measured with [15O]H2O PET, and BOLD signal was measured with fMRI, both during an n-back working memory paradigm. Global Assessment of Functioning Scale (GAF) scores and clinical characteristics were obtained for each patient before hormone manipulation, and symptoms were measured before and during the protocol. RESULTS: In both the PET and fMRI studies, a main effect of diagnosis was observed, with PMDD patients showing greater prefrontal activation than comparison subjects. In the patient group, the degree to which dorsolateral prefrontal cortex activation was abnormally increased correlated with several dimensions of disease: disability as indicated by GAF scores, age at symptom onset, duration of PMDD, and differences in pre- and postmenses PMDD symptoms. CONCLUSIONS:Abnormal working memory activation in PMDD, specifically in the dorsolateral prefrontal cortex, is related to PMDD severity, symptoms, age at onset, and disease burden. These results support the clinical relevance of the findings and the proposal that dorsolateral prefrontal cortex dysfunction represents a substrate of risk for PMDD. The concordance of the fMRI and PET data attests to the neurobiological validity of the results.
Authors: Xenia Protopopescu; Oliver Tuescher; Hong Pan; Jane Epstein; James Root; Luke Chang; Margaret Altemus; Margaret Polanecsky; Bruce McEwen; Emily Stern; David Silbersweig Journal: J Affect Disord Date: 2007-11-26 Impact factor: 4.839
Authors: D R Rubinow; M C Hoban; G N Grover; D S Galloway; P Roy-Byrne; R Andersen; G R Merriam Journal: Am J Obstet Gynecol Date: 1988-01 Impact factor: 8.661
Authors: C Neill Epperson; Kristin Haga; Graeme F Mason; Edward Sellers; Ralitza Gueorguieva; Wenjiang Zhang; Erica Weiss; Douglas L Rothman; John H Krystal Journal: Arch Gen Psychiatry Date: 2002-09
Authors: Kristina M Deligiannidis; Christina L Fales; Aimee R Kroll-Desrosiers; Scott A Shaffer; Vanessa Villamarin; Yanglan Tan; Janet E Hall; Blaise B Frederick; Elif M Sikoglu; Richard A Edden; Anthony J Rothschild; Constance M Moore Journal: Neuropsychopharmacology Date: 2018-10-17 Impact factor: 7.853
Authors: S-M Wei; E B Baller; P D Kohn; J S Kippenhan; B Kolachana; S J Soldin; D R Rubinow; P J Schmidt; K F Berman Journal: Mol Psychiatry Date: 2017-04-18 Impact factor: 15.992